Xeris Biopharma Holdings, Inc. provided earnings guidance for the year 2024. The momentum continues in 2024 as the company expects to grow total revenue in the range of $170 million to $200 million. This double-digit revenue growth, coupled with recent debt refinancing and continued disciplined cash management, will allow the company to further invest in all aspects of business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.355 USD | +0.64% |
|
+11.61% | +0.21% |
Jul. 08 | Xeris Biopharma Appoints John Shannon as CEO | MT |
Jul. 08 | Xeris Biopharma Holdings, Inc. Announces CEO Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.21% | 349M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024